UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of September 2017
COMMISSION
FILE Number.
000-29338
CARDIOME
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Exhibit |
|
Description |
|
|
|
99.1 |
|
News Release dated September 5, 2017 - Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference |
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
CARDIOME
PHARMA CORP. |
|
(Registrant) |
|
|
|
Date: September 5, 2017 |
By: |
/s/
Justin Renz |
|
|
Name: Justin Renz |
|
|
Title: Chief Financial Officer |
Exhibit 99.1
Cardiome to Present at the Rodman & Renshaw 19th
Annual Global Investment Conference
NASDAQ: CRME TSX: COM
VANCOUVER, Sept. 5, 2017 /CNW/ - Cardiome Pharma Corp.
(NASDAQ: CRME / TSX: COM) today announced that Dr. Bill Hunter, President and CEO of Cardiome, will provide an update on the company's
progress at the Rodman & Renshaw 19th Annual Global Investment Conference. The presentation will take place at the Lotte New
York Palace on Monday September 11, 2017 at 11:40 a.m. EDT.
The webcast of Dr. Hunter's presentation can be accessed through
the following link:
http://wsw.com/webcast/rrshq27/crme/
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company
dedicated to the development and commercialization of innovative therapies that will improve the quality of life and health of
patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS® (vernakalant
IV), approved in Europe, Canada, and other countries for the rapid conversion of recent onset atrial fibrillation to sinus rhythm
in adults, and AGGRASTAT® (tirofiban hydrochloride) a reversible GP IIb/IIIa inhibitor indicated for use in patients
with acute coronary syndrome. Cardiome also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride),
a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, on behalf of their partner
Amomed in select European markets. Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second
generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections
(ABSSSI) in adults for select European and Middle Eastern countries and Canada from Allergan; and TREVYENT®, a development
stage drug device combination that is under development for Pulmonary Arterial Hypertension for Europe, the Middle East and for
Canadian markets from SteadyMed Therapeutics.
Cardiome is traded on the NASDAQ Capital Market (CRME) and
the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the
words "believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Forward-looking statements may involve, but are not limited to,
comments with respect to our objectives and priorities for 2017 and beyond, our strategies or future actions, our targets, expectations
for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others, the following: general economic and business conditions
in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could
impact our existing or future products; competition; existing governmental legislation and regulations and changes in, or the failure
to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and
third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing
of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial
funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business
is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business
strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting
from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance our activities. These and other risks are described in the
Form 40F and associated documents filed March 29, 2017 (see for example, "Risk Factors" in the Annual Information Form
for the year ended December 31, 2016), in the Form 6-K filed August 10, 2017, and in our other filings with the Securities and
Exchange Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements
and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information
made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements
and information to reflect subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
View original content: http://www.newswire.ca/en/releases/archive/September2017/05/c3938.html
%CIK: 0001036141
For further information: Justin Renz, CFO, Cardiome Pharma
Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@cardiome.com
CO: Cardiome Pharma Corp.
CNW 08:00e 05-SEP-17
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024